Galera Therapeutics, Inc.
OTC: GRTX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- J. Mel Sorensen
- Employees
- 3
- Headquarters
- Malvern, United States
- IPO year
- 2019
- Market cap
- $7.0M
- Website
- https://www.galeratx.com
Loading GRTX…
Loading profile data…Frequently asked questions about GRTX
What does Galera Therapeutics, Inc. (GRTX) do?
Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation and commercialization of therapies aimed at revolutionizing cancer radiotherapy. Its lead investigational drug, avasopasem manganese (GC4419), functions as a small molecule superoxide dismutase mimetic. This compound has successfully co...
Where does GRTX trade?
Galera Therapeutics, Inc. (GRTX) trades on the Other OTC.
What sector is GRTX in?
Galera Therapeutics, Inc. (GRTX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Galera Therapeutics, Inc.?
J. Mel Sorensen is the chief executive officer of Galera Therapeutics, Inc. (GRTX).
Where is Galera Therapeutics, Inc. headquartered?
Galera Therapeutics, Inc. is headquartered in United States.
Does GRTX pay a dividend?
Galera Therapeutics, Inc. (GRTX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did GRTX go public?
Galera Therapeutics, Inc. (GRTX) completed its initial public offering in 2019.